ECSP10010210A - Compuestos nucleósidos antivirales - Google Patents

Compuestos nucleósidos antivirales

Info

Publication number
ECSP10010210A
ECSP10010210A EC2010010210A ECSP10010210A ECSP10010210A EC SP10010210 A ECSP10010210 A EC SP10010210A EC 2010010210 A EC2010010210 A EC 2010010210A EC SP10010210 A ECSP10010210 A EC SP10010210A EC SP10010210 A ECSP10010210 A EC SP10010210A
Authority
EC
Ecuador
Prior art keywords
compounds
nucleosid
antiviral
treatment
hepatitis
Prior art date
Application number
EC2010010210A
Other languages
English (en)
Inventor
Scott J Hecker
David Bernard Smith
Brett C Bookser
K Raja Reddy
Zhili Sun
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010210(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Publication of ECSP10010210A publication Critical patent/ECSP10010210A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos que poseen la fórmula I o II en la que R1, R2, B, y V son tal como se ha definido aquí son inhibidores de la polimerasa NS5b del virus de la hepatitis C. También se describen composiciones y métodos para el tratamiento de una infección por VHC y que inhiben la replicación de VHC.
EC2010010210A 2007-11-29 2010-05-28 Compuestos nucleósidos antivirales ECSP10010210A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99116307P 2007-11-29 2007-11-29
US8454408P 2008-07-29 2008-07-29

Publications (1)

Publication Number Publication Date
ECSP10010210A true ECSP10010210A (es) 2010-08-31

Family

ID=40679083

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010210A ECSP10010210A (es) 2007-11-29 2010-05-28 Compuestos nucleósidos antivirales

Country Status (20)

Country Link
US (2) US8063025B2 (es)
EP (1) EP2227481A4 (es)
JP (1) JP2011505351A (es)
KR (1) KR20100103793A (es)
CN (1) CN102164939A (es)
AR (1) AR069740A1 (es)
AU (1) AU2008331158A1 (es)
BR (1) BRPI0819797A2 (es)
CA (1) CA2706432A1 (es)
CL (1) CL2008003511A1 (es)
CO (1) CO6382185A2 (es)
CR (1) CR11453A (es)
EC (1) ECSP10010210A (es)
IL (1) IL205625A0 (es)
MA (1) MA31864B1 (es)
MX (1) MX2010005885A (es)
RU (1) RU2010126050A (es)
TW (1) TW200936146A (es)
WO (1) WO2009069095A2 (es)
ZA (1) ZA201003438B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2525237T3 (es) 2007-11-29 2014-12-19 Boehringer Ingelheim International Gmbh Derivados de amidas del ácido 6,7-dihidro-5H-imidazo[1,2-a]imidazol-3-carboxílico
MX337050B (es) * 2010-01-28 2016-02-10 Riboscience Llc Compuestos 4'-azido-nucleósidos como anti-vhc.
AU2011305652B2 (en) 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
WO2013070887A1 (en) * 2011-11-10 2013-05-16 Inhibitex, Inc. Substituted purine nucleosides, phosphoramidate and phosphordiamidate derivatives for treatment of viral infections
US9676809B2 (en) 2013-11-22 2017-06-13 Ligand Pharmaceuticals Incorporated Derivatives of uridine 5′-cyclophosphate useful to treat hepatitis C viral infections
CN103848877B (zh) * 2013-12-16 2016-08-24 安徽贝克联合制药有限公司 核苷环磷酸酯化合物及其制备方法和其应用
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
JP2017520545A (ja) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
AU2016302005B2 (en) 2015-08-05 2021-03-04 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
US20190350960A1 (en) 2017-01-04 2019-11-21 President And Fellows Of Harvard College Modulating nudix homology domain (nhd) with nicotinamide mononucleotide analogs and derivatives of same
CN108727450B (zh) * 2017-04-18 2024-02-20 浙江柏拉阿图医药科技有限公司 肝递送抗丙肝前体药物核苷环磷酸酯化合物及应用
CN109956986B (zh) * 2017-12-22 2021-04-27 浙江柏拉阿图医药科技有限公司 肝递送吉西他滨前体药物核苷环磷酸酯化合物及应用
CN109956975B (zh) * 2017-12-22 2020-11-06 浙江柏拉阿图医药科技有限公司 肝递送恩替卡韦前体药物核苷环磷酸酯化合物及应用
CN109956985A (zh) * 2017-12-22 2019-07-02 浙江柏拉阿图医药科技有限公司 肝递送阿糖胞苷前体药物核苷环磷酸酯化合物及应用
CA3087932A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
CN111434671B (zh) * 2019-01-11 2023-07-11 凯思凯迪（上海）医药科技有限公司 肝脏特异性ampk激动剂及其制法和应用
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
EP4106876B1 (en) 2020-02-18 2025-09-17 Gilead Sciences, Inc. Antiviral compounds
KR102923359B1 (ko) 2021-04-16 2026-02-05 길리애드 사이언시즈, 인코포레이티드 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
EP4387977A1 (en) 2021-08-18 2024-06-26 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4741725B2 (ja) * 1998-03-06 2011-08-10 メタベイシス・セラピューティクス・インコーポレーテッド リン含有化合物のための新規なプロドラッグ
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
BR0315795A (pt) * 2002-10-31 2005-09-13 Metabasis Therapeutics Inc Pró-medicamentos de monofosfato de citarabina
TWI332507B (en) * 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
CN1852915A (zh) * 2003-07-25 2006-10-25 艾登尼科斯（开曼）有限公司 治疗包括丙型肝炎的黄病毒科病毒所致疾病的嘌呤核苷类似物
JP2008508319A (ja) 2004-07-29 2008-03-21 メタバシス・セラピューティクス・インコーポレイテッド 新規ヌクレオシド誘導体
CN101287472B (zh) * 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
JP4954573B2 (ja) * 2006-02-28 2012-06-20 オリンパス株式会社 内視鏡システム

Also Published As

Publication number Publication date
MA31864B1 (fr) 2010-11-01
EP2227481A2 (en) 2010-09-15
RU2010126050A (ru) 2012-01-10
CL2008003511A1 (es) 2010-02-19
WO2009069095A2 (en) 2009-06-04
MX2010005885A (es) 2010-11-24
AR069740A1 (es) 2010-02-17
US20120039845A1 (en) 2012-02-16
CA2706432A1 (en) 2009-06-04
EP2227481A4 (en) 2011-03-09
AU2008331158A1 (en) 2009-06-04
CO6382185A2 (es) 2012-02-15
JP2011505351A (ja) 2011-02-24
US8063025B2 (en) 2011-11-22
ZA201003438B (en) 2011-04-28
US20090209481A1 (en) 2009-08-20
TW200936146A (en) 2009-09-01
CN102164939A (zh) 2011-08-24
KR20100103793A (ko) 2010-09-28
BRPI0819797A2 (pt) 2019-09-24
CR11453A (es) 2010-10-27
IL205625A0 (en) 2010-11-30
WO2009069095A3 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
ECSP10010210A (es) Compuestos nucleósidos antivirales
CO6400218A2 (es) Compuestos heterocíclicos antivirales
CL2019000271A1 (es) Inhibidores de polimerasa hcv. (divisional solicitud 201600493)
CR10136A (es) Nucleósidos antivirales
ECSP12012282A (es) Fosforamidatos de nucleósido
CL2009000305A1 (es) Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv).
ECSP10010618A (es) Análogos carba - nucleósidos para tratamiento antiviral
CL2009002207A1 (es) Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
CY1118111T1 (el) Υποκατεστημενα αλειφανια, κυκλοφανια, ετεραφανια, ετεροφανια, ετερο-ετεραφανια και μεταλλοκενια που ειναι χρησιμα για τη θεραπευτικη αντιμετωπιση hcv λοιμωξεων
CO6430431A2 (es) Inhibidores del virus de la hepatitis c
CO6561788A2 (es) Inhibidores del virus de la hepatitis c
UY33097A (es) DERIVADOS DE (1h-PIRAZOL-5-IL)UREIDOARILO 1,3-DISUSTITUIDOS Y SUS USOS TERAPÉUTICOS
CL2011002830A1 (es) Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c.
MX2020002151A (es) Compuestos antivirales.
CL2011000145A1 (es) Compuesto macrociclico derivado de quinoxalina y sus sales; inhibidor de la proteasa ns3 del virus de la hepatitis c(hcv); composicion farmaceutica que lo comprende; y uso en la prevencion o el tratamiento de una infeccion por hcv.
ECSP11011310A (es) Análogos carba - nucleósido para tratamiento antiviral
CO6361922A2 (es) Inhibidores del virus de la hepatitis c
MX2012003170A (es) Compuestos heterociclicos antivirales.
UY28581A1 (es) Compuestos nucleosidicos para el tratamiento de infecciones virales
CL2011001364A1 (es) Compuestos derivados de nucleotidos de uracil ciclopropilicos, inhibidores de la polimerasa del virus de la hepatitis c; composiciones farmaceuticas; y uso del compuesto para el tratamiento de hepatitis c (hcv).
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
UY30127A1 (es) Derivados de acidos antranilicos fenoxi y feniltio, composiciones farmaceuticas que los contienen y su uso.
CL2008002291A1 (es) Compuestos derivados del acido 4-fluor-benzoico, inhibidores de la polimerasa hcv, composicion farmaceutica, kit farmaceutico y su uso para el tratamiento de una infeccion viral por hepatitis c.
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados